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Effects of formoterol or salmeterol on impulse
oscillometry in patients with persistent asthmaArvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff, PhD, Ashley Morrison, BScN, and
Brian J. Lipworth, MD Dundee, United KingdomBackground: Effects of small-particle long-acting b-agonists on
the small airways have been poorly documented.
Objective: We used impulse oscillometry (IOS) to compare
single and repeated dosing effects of small- and large-particle
long-acting b-agonists.
Methods: After a 1- to 2-week run-in period, patients received
either 12 mg of small-particle hydrofluoroalkane 134a–
formoterol solution or 50 mg of large-particle salmeterol dry
powder twice daily plus inhaled corticosteroid for 1 to 2 weeks
with a 1- to 2-week washout period in between. Measurements
were made over 60 minutes after the first and last doses.
Results: Sixteen patients completed the study as follows: mean
age, 43 years; FEV1, 80%; forced midexpiratory flow between
25% and 75% of forced vital capacity (FEF25-75), 48%; total
airway resistance at 5 Hz, 177%; peripheral airway resistance
as the difference between 5 and 20 Hz, 0.18 kPa$L21$s; Asthma
Control Questionnaire score, 0.76; and inhaled corticosteroid
dosage, 550 mg/d. There were significantly greater
improvements with formoterol versus salmeterol in all IOS
outcomes and FEF25-75, but not FEV1, at 5 minutes after the first
dose, which were not sustained over 60 minutes. After the last
dose, all IOS outcomes, but not FEV1 or FEF25-75, were
significantly better with formoterol over the entire 60 minutes:
mean difference at 60 minutes between formoterol and
salmeterol in total airway resistance at 5 Hz, 7.50% (95% CI,
1.56% to 13.43%, P 5 .02); central airway resistance at 20 Hz,
5.37% (95% CI, 0.13% to 10.62%, P 5 .045); peripheral airway
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19.46% (95% CI, 7.56% to 31.36%, P 5 .003); reactance at
5 Hz, 11.19% (95% CI, 4.62% to 17.76%, P 5 .002); and
resonant frequency, 9.34% (95% CI, 3.21% to 15.47%,
P 5 .005). Peak expiratory flow significantly improved to a
similar degree with both drugs.
Conclusion: Significant improvements in IOS outcomes but not
spirometry results occurred after chronic dosing with
formoterol compared with salmeterol. This might reflect better
deposition to the entire lung, including the small airways. (J
Allergy Clin Immunol 2016;137:727-33.)
Key words: Asthma, small airways, spirometry, impulse oscillome-
try, long-acting b-agonist, formoterol, salmeterol
Inhaled corticosteroid (ICS) with long-acting b-agonist
(LABA) combination inhalers are now well established in current
management guidelines as the preferred form of controller therapy
in patients with persistent asthma. There is now increasing
evidence to support a distinct asthma phenotype characterized
by the presence of a disproportionate degree of persistent small-
airways dysfunction.1 It is possible to assess small-airways
dysfunction in the so-called ‘‘silent zone’’ by using impulse oscill-
ometry (IOS) tomeasure peripheral airway resistance as the differ-
ence between 5 and 20 Hz (R5-20) or peripheral airway
capacitance as either the reactance area under the curve (AX) or
reactance at 5 Hz (X5), as well as resonant frequency (RF).2,3
Spirometry can be used to derive volume-dependent airways
closure as the forced expiratory flow between 25% and 75% of
forced vital capacity (FEF25-75). IOS is an effort-independent test
performed during normal tidal breathing to measure the fre-
quency dependence of soundwaves emanating from the bronchial
tree and is considered more physiologic than spirometry, which
tends to exaggerate small-airways closure associated with forced
expiration.1 Moreover, IOS is much easier and quicker to perform
than spirometry, making it well suited to routinemeasurement in a
busy clinic setting. Patients with the small-airways asthma pheno-
type who exhibit well-preserved FEV1 in conjunction with
abnormal R5-20 or FEF25-75 values, which in turn confers an
increased risk of poorer long-term asthma control.4 In a prospec-
tive study one IOS parameter (AX) showed sustained improve-
ment over a prolonged period of follow-up in asthmatic
children receiving controller therapy compared with spirometry.5
The advent of a small-particle hydrofluoroalkane 134a (HFA)–
beclomethasone/formoterol combination solution metered-dose
inhaler (Chiesi, Cheadle, United Kingdom) has provided the
opportunity to target the entire lung in terms of both anti-
inflammatory and smooth muscle responses in asthmatic patients
associated with respective effects of ICS and LABA moieties.
Although several clinical studies have attempted to differentiate
between the effects of ICS formulations with different particle727
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728 MANOHARAN ET ALAbbreviations usedACQ: Asthma Control QuestionnaireAX: Reactance area under the curveFEF25-75: Forced midexpiratory flow between 25% and 75% of forced
vital capacityFENO: Fraction of exhaled nitric oxideHFA: Hydrofluoroalkane 134aICS: Inhaled corticosteroidIOS: Impulse oscillometryLABA: Long-acting b-agonistPEF: Peak expiratory flowR5: Total airway resistance at 5 HzR5-20: Peripheral airway resistance as the difference between 5 and
20 HzR20: Central airway resistance at 20 HzRF: Resonant frequencyX5: Reactance at 5 Hzsizes,6-11 relatively little attention has been given to the effects of
LABA formulations on the small airways.1
The aim of the present proof-of-concept study was to assess the
effect of particle size on bronchodilator response with IOS using 2
different LABAscurrently licensed for add-on to ICSs in theUnited
Kingdom, namely the 12-mg small-particle HFA-formoterol solu-
tion metered-dose inhaler (Chiesi) and 50-mg large-particle
salmeterol dry powder inhaler (GlaxoSmithKline, Uxbridge,
United Kingdom), which were chosen to represent 2 extremes of
mass median aerodynamic diameter at 0.80 and 3.64 mm, respec-
tively.12,13 It is generally considered that particles less than 2mm in
diameter are able to optimally penetrate the small airways,1 which
is the reason for choosing the 2 formulations at different ends of the
particle size spectrum.We elected to usewhat are normally consid-
ered therapeutically equivalent doses of formoterol (12-mg nominal
ex valve dose5 10.1-mg delivered ex actuator dose) and salmeterol
(50-mg nominal ex valve dose5 47-mg delivered dose).14
Specifically, wewanted to dissect out the independent effects of
the different LABAs to obviate any potential confounding effect
of different ICS moieties in their respective combination inhalers.
Hence we decided to provide each LABA inhaler in addition to
the same reference ICS therapy (as large-particle beclometha-
sone), with evaluation of airway responses after single and
repeated dosing by using IOS and spirometry. Another reason
for choosing the respective LABAs (rather than comparing small-
and large-particle formoterol) is that the results from this study
would presage a subsequent chronic dosing comparison of
combination inhalers, namely 200/12 mg beclomethasone/for-
moterol solution (Chiesi) versus 250/50mg fluticasone/salmeterol
dry powder (GlaxoSmithKline).METHODS
Study participants
Inclusion criteriaweremale or female volunteers aged at least 16 years with
a diagnosis of persistent asthma, total airway resistance at 5 Hz (R5) of greater
than 150% of predicted value, R5-R20 value of 0.05 kPa$L21$s despite
receiving ICS or ICS/LABA treatment, and FEV1 of greater than 60%. Exclu-
sion criteria were other significant respiratory diseases, an asthma exacerba-
tion or respiratory tract infection requiring systemic steroids and/or
antibiotics within 3 months of study commencement, and smoking within
1 year or a greater than 10 pack year history.Study design
We carried out a single-center, randomized, open-label, crossover study
(Fig 1). Patients were randomized to either 50 mg of dry powder inhaler sal-
meterol (GlaxoSmithKline) twice daily or 12 mg of HFA-formoterol solution
(Chiesi) twice daily. The primary outcome was percentage change in R5-R20
frombaseline. Secondary outcomes included percentage change frombaseline
in the remaining IOS variables (R5, central airway resistance at 20 Hz [R20],
X5, RF, and AX), spirometry (FEV1 and FEF25-75), domiciliary peak expira-
tory flow (PEF), Asthma Control Questionnaire (ACQ) score, and fraction of
exhaled nitric oxide (FENO).
At the screening visit, participants were converted to a reference HFA-
beclomethasone dipropionate inhaler (Chiesi) with a mass median aero-
dynamic diameter of 2.9 mm15 at an equivalent beclomethasone dipropionate
dose, and any concomitant LABAwas also stopped. After a 1- to 2-week run-
in period, at visit 1, baseline measurements for IOS, spirometry, ACQ score,
and FENO value were recorded. The first dose of the study inhaler was then
administered in the department. IOS and spirometry were repeated at 5, 15,
30, 45, and 60 minutes after the first dose. After 1 to 2 weeks on the study
inhaler, participants returned to the department for visit 2, with the penulti-
mate dose of study inhaler being taken 12 hours before the study visit. Baseline
measurements for the chronic dosing visit were recorded, and the last dose of
the study inhaler was then administered. IOS and spirometry outcomes were
recorded over 60 minutes as per after the first dose. Participants subsequently
entered a wash-out period of 1 to 2 weeks, after which the same process was
repeated with the other study inhaler after crossover at visits 3 and 4.Measurements
IOS (Masterscreen IOS, H€ochberg, Germany) was performed in triplicate,
according to the manufacturer’s guidelines. Spirometry was performed with a
SuperSpiro (MicroMedical, Chatham,Kent,UnitedKingdom), andFENO values
were measured with a NIOX analyzer (NIOX Nitric Oxide Monitoring System;
Aerocrine AB, Solna, Sweden), according to American Thoracic Society
guidelines.16,17 Asthma control was assessed by using the 6-item ACQ.18,19Ethics
The East of Scotland Research Ethics Service granted ethical approval
(reference 13/ES/0050), and all patients provided written informed consent.Statistical analyses
Sample size estimates were based on previous IOS data,20 such that 16 pa-
tients would be required to complete per protocol to detect a 20% difference in
the primary outcome of R5-20 achieving 80% power with an a error of .05 (2-
tailed). We compared baselines according to treatment before the first and last
doses of formoterol versus salmeterol. The respective baselineswere then used
to calculate the percentage changes for IOS and spirometry after single and
chronic dosing. Repeated-measures ANOVA was applied to assess any
treatment-time interaction over the 60-minute profile after single or repeated
dosing. Hence the absence of a significant interaction indicates that any detect-
able differences between treatments are consistent over the 60minutes, in turn
resulting in a 95% CI for the overall treatment difference that excludes zero.
Data for domiciliary peak flow were calculated as the average values from
the last 3 days of the run-in, washout, and each repeated treatment period
and were then compared by using paired Student t tests. SPSS version 21
(SPSS, Chicago, Ill) was used for all analyses.RESULTS
Participant flow through the study is shown in Fig 2. Sixteen pa-
tients completed per protocol: mean age, 43 years; FEV1, 80%;
R5, 177%;R5-20, 0.18 kPa$L21$s; andACQ score, 0.76 (Table I).
Baseline values before single or repeated dosing were not
significantly different when comparing formoterol versus salme-
terol (Table II). There were no differences when comparing
FIG 1. After a 1- to 2-week run-in period, patients received either 12 mg of small-particle HFA-formoterol or
50 mg of large-particle salmeterol dry powder 1 puff twice daily for 1 to 2 weeks each, with a 1- to 2-week
washout period in between. Visits 1 and 3 were to assess the first dose, and visits 2 and 4 were to assess the
last dose. At each visit, measurements weremade at baseline and then over 60minutes after inhalation.DPI,
Dry powder inhaler.
FIG 2. CONSORT diagram to show flow of participants through the study.
TABLE I. Demographics at screening
Age (y) 43 (4.2)
Male/female sex 9/7
BDP equivalent dose 550 (74)
LABA (%) 50
ACQ-6 score 0.76 (0.17)
FENO (ppb) 27 (3.0)
FEV1 (% predicted) 80 (2.5)
FVC (% predicted) 94 (3.1)
FEF25-75 (% predicted) 48 (4.5)
FEV1/FVC ratio 0.72 (0.02)
R5 (kPa$L21$s) 0.56 (0.04)
R5 (% predicted) 177 (12)
R20 (kPa$L21$s) 0.38 (0.02)
R5-R20 (kPa$L21$s) 0.18 (0.03)
X5 (kPa$L21$s) 20.24 (0.03)
RF (Hz) 21.5 (1.2)
AX (kPa$L21) 1.92 (0.35)
All values are shown as means and SEMs.
BDP, Beclomethasone dipropionate; FVC, forced vital capacity.
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periods, respectively.
After single dosing, the overall treatment response (ANOVA
over 60 minutes) comparing formulations was not significantly
different with IOS or spirometry, as indicated by 95% CIs for the
difference that included zero for the percentage change from
respective baseline (see Table E1 in this article’s Online Reposi-
tory at www.jacionline.org). Moreover, there was a significant
treatment-time interaction for all IOS outcomes, indicating that
any differences between formulations were not consistent over
the 60-minute time period (Fig 3). A significantly greater
response was seen with formoterol versus salmeterol at 5 minutes
for all IOS outcomes and for FEF25-75 but not FEV1, which is in
keeping with a faster speed of onset (Table III).
After repeated dosing, there were significant overall improve-
ments (ANOVA over 60 minutes) conferred by formoterol over
salmeterol for all IOS outcomes, as indicated by 95% CIs for the
difference that excluded zero for the percentage change fromrespective baseline (Table IV). The treatment-time interaction
was nonsignificant for all IOS outcomes, indicating that such
differences were consistent over the entire 60-minute period
(Fig 4).
No significant differences between formoterol and salmeterol
were seen in spirometry outcomes (FEV1 or FEF25-75) after
repeated dosing (Table IV).
Mean domiciliary peak flow measurements showed significant
but similar improvements with both formoterol (from 442 to
474 L/min, P 5 .002) and salmeterol (from 450 to 474 L/min,
P < .001) after repeated dosing versus baseline. Mean ACQ-6
scores were not significantly different after repeated dosing
when comparing values between formoterol (0.48) and salmeterol
(0.52). FENO values were not significantly altered after formoterol
or salmeterol, with levels of 22.5 and 23.6 ppb, respectively.DISCUSSION
The results of the present study showed significantly greater
improvements in all IOS outcomes conferred by small-particle
formoterol in terms of total (R5), central (R20), and peripheral
airway resistance (R5-20) and AX and X5, as well as RF. These
TABLE II. Baselines according to treatment for IOS and spirometry
Acute baseline Chronic baseline
Salmeterol Formoterol P value Salmeterol Formoterol P value
FEV1 (L) 2.61 (2.27 to 2.94) 2.62 (2.30 to 2.94) .84 2.72 (2.38 to 3.06) 2.69 (2.33 to 3.06) .47
FEF25-75 (L$s
21) 1.85 (1.54 to 2.16) 1.76 (1.42 to 2.09) .17 1.92 (1.56 to 2.28) 1.97 (1.57 to 2.36) .53
R5 (kPa$L21$s) 0.60 (0.51 to 0.68) 0.58 (0.51 to 0.65) .42 0.50 (0.44 to 0.56) 0.52 (0.46 to 0.58) .40
R20 (kPa$L21$s) 0.39 (0.36 to 0.43) 0.39 (0.35 to 0.42) .76 0.36 (0.33 to 0.39) 0.37 (0.34 to 0.41) .38
R5-R20 (kPa$L21$s) 0.20 (0.14 to 0.27) 0.19 (0.12 to 0.25) .46 0.14 (0.09 to 0.19) 0.15 (0.11 to 0.18) .68
X5 (kPa$L21$s) 20.25 (20.31 to 0.19) 20.24 (20.30 to 0.18) .76 20.19 (20.23 to 20.16) 20.20 (20.24 to 20.15) .68
RF (Hz) 24.4 (21.1 to 27.7) 23.3 (20.4 to 26.2) .30 20.60 (17.67 to 23.53) 20.24 (17.53 to 22.95) .60
AX (kPa$L21) 2.35 (1.52 to 3.18) 2.13 (1.38 to 2.88) .54 1.45 (0.98 to 1.92) 1.48 (0.96 to 2.00) .83
P values refer to the comparison between salmeterol and formoterol for baseline values before the first (acute) or last (chronic) dose. Values are shown as means (95% CIs).
FIG 3. Effects on IOS outcomes with either small-particle formoterol or large-particle salmeterol over a
60-minute period after inhaling the first dose shown as the percentage change from baseline. Data are
depicted as means and SEMs. For all IOS outcomes, there were significant differences at 5 minutes, which
were not sustained over the entire 60-minute period.
TABLE III. Percentage change from baseline at 5 minutes after
the first dose
Salmeterol
(% change)
Formoterol
(% change)
Difference
(%)
P
value
FEV1 3.40 6.43 3.04 (21.39 to 7.46) .16
FEF25-75 4.74 13.37 8.63 (0.85 to 16.41) .03
R5 16.77 24.93 8.16 (3.21 to 13.11) .003
R20 5.71 10.95 5.23 (0.03 to 10.43) .049
R5-R20 37.87 53.05 15.18 (5.76 to 24.59) .004
X5 24.37 35.62 11.25 (1.79 to 20.72) .02
RF 18.90 28.21 9.31 (3.72 to 14.90) .003
AX 44.93 58.92 13.99 (4.24 to 23.75) .008
Mean values are shown for each drug, as well as the difference (as 95% CIs).
TABLE IV. Percentage change from baseline over 60 minutes
after the last dose
Salmeterol
(% change)
Formoterol
(% change) Difference (%)
P
value
FEV1 3.15 5.81 2.65 (20.66 to 5.96) .11
FEF25-75 9.93 13.5 3.57 (24.99 to 12.14) .39
R5 6.11 13.60 7.50 (1.56 to 13.43) .02
R20 1.45 6.82 5.37 (0.13 to 10.62) .045
R5-R20 18.36 31.12 12.76 (1.28 to 24.24) .03
X5 9.29 20.48 11.19 (4.62 to 17.76) .002
RF 8.70 18.04 9.34 (3.21 to 15.47) .005
AX 18.81 38.27 19.46 (7.56 to 31.36) .003
Mean values are shown for each drug, as well as the difference (as 95% CIs).
J ALLERGY CLIN IMMUNOL
MARCH 2016
730 MANOHARAN ET ALchanges in IOS outcomes occurred after repeated dosing with
12 mg of twice-daily formoterol compared with 50 mg of twice-
daily salmeterol when used as add-on to ICSs in controlled
patients with mild-to-moderate persistent asthma. Moreover, the
differences between formulations for all of the IOS outcomes
were sustained over the entire 60-minute period after inhaling the
last dose. The greater reduction in central and peripheral
resistance might reflect enhanced distribution of formoterol
throughout the lung, including the small airways, which is inkeeping with its finer particle size. No such differences were seen
for FEV1, FEF25-75, or domiciliary PEF after repeated dosing.
The apparent disconnect in IOS outcomes between single and
chronic dosing might be explained by the cumulative effects of
extrafine particles on the smaller airways on repeated exposure,
resulting in subtle changes in airway geometry. In other words, it is
possible that equilibrationwas achieved at steady state for regional
bronchodilator effects, which improved the overall signal/noise
ratio seen with IOS after repeated but not single dosing.
FIG 4. Effects on IOS outcomes with either small-particle formoterol or large-particle salmeterol over a
60-minute period after inhaling the last dose shown as percentage change from baseline. Data are depicted
as means and SEMs. For all IOS outcomes, there were significant differences between treatments, which
were sustained over the 60-minute period.
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different pharmacologic properties. If the faster speed of onset
with formoterol was the explanation for the greater improvement
in IOS outcomes after the last dose, then one would expect to see
the same difference between LABAs maintained over the entire
60-minute profile after both single and repeated dosing, which
was not observed in the present study. The other pharmacologic
possibility to explain the observed difference in IOS outcomes
after repeated dosing could be the greater degree of b2-receptor
intrinsic agonist activity when comparing formoterol (full
agonist) and salmeterol (partial agonist). However, one would
predict that the higher agonist activity of formoterol would pro-
duce more b2-receptor downregulation and associated subsensi-
tivity of response than salmeterol after the last dose, whereas
the opposite was seen.
In a previous comparison of single doses of large-particle
metered-dose inhaler formulations of 24 mg of formoterol or
50 mg of salmeterol administered through a large-volume
spacer in patients with moderately severe asthma, there was a
significantly greater response on FEV1 with formoterol at
10 minutes but not at any other time points in the first 60 mi-
nutes after inhalation.21 In the same study specific airway
conductance showed sustained improvements with formoterol
over the entire 60 minutes, with there being no difference be-
tween 4 and 12 hours after inhalation, although no chronic
dosing assessment was performed. This confirms the greater
sensitivity of measuring airway resistance (its reciprocal as
Gaw) over dynamic lung volumes (as FEV1), which was also
seen in our study when comparing R5 and FEV1, although
we used formoterol without a spacer. The use of a large-
volume spacer would result in an increase in overall respirable
dose and an associated reduction in particle size. Hence 24 mg
of formoterol would normally be considered therapeutically
equivalent to 100 mg rather than 50 mg of salmeterol, which
might explain the observed superiority in the study by Van
Noord et al.21 The fast onset with formoterol forms the basis
of its licensed indication for use as both maintenance andreliever therapy during chronic dosing when using a single
ICS/LABA combination inhaler, such as a beclomethasone/
formoterol pressurized metered-dose inhaler.22
We performed our measurements at steady state to correspond
with the end of the usual 12-hour dosing interval, reflecting a
twice-daily regimen with LABAs. This period at trough repre-
sents a time in the day when the patient might be at their most
vulnerable to potential bronchoconstrictor stimuli before taking
the next dose. At steady state with repeated dosing, the airway
caliber will be slightly higher because of some residual b2-recep-
tor occupancy at trough, as was shown when comparing the
respective baseline values before the first and last doses of
each LABA.
We defined bronchodilator response as the percentage change
from respective baseline values after the first and last dose
because we believed this best reflected the relative changes in
airway caliber. Thus therewill inevitably be an apparent degree of
blunting of the magnitude of the percentage response from the
higher baseline value when comparing effects after repeated
versus single dosing. Pointedly, we found no significant differ-
ences between the respective baseline values for salmeterol
versus formoterol before the last dose. In turn, this allowed us
to make valid head-to-head comparisons between the 2 formula-
tions after repeated dosing. It is also worth mentioning that we
observed no differences when comparing baseline values between
visits 1 and 3 after the run-in and washout periods, respectively,
confirming that there were no carryover effects between the
randomized treatment arms. This is to be expected because the
duration of washout of at least 1 week (ie, 168 hours) exceeded a
period of 5 half-lives for either LABA (ie, 60 hours).
Our data showed that after the last dose, the 95% CI for the
overall mean difference (ie, over 60minutes) excluded zero for all
IOS outcomes, which is in keeping with significantly sustained
improvements in both total and peripheral airways resistance and
reactance. The density of b2-receptors is higher in the distal than
proximal airways,23 perhaps also reflecting the greater overall
relative surface area in the small airways. This needs to be
J ALLERGY CLIN IMMUNOL
MARCH 2016
732 MANOHARAN ET ALconsidered against the amount by which airway smooth muscle
reduces proportionately from the proximal to distal airways.
We appreciate that the observed differences in IOS outcomes
might not translate into improvements in symptom control. It has
been shown that R5-R20 and AX values, but not FEV1, correlate
to health status, dyspnea, and disease control.24 In another study
comparing asthmatic patients with and without symptoms who
underwent a methacholine challenge, the symptomatic group ex-
hibited a significantly greater change in R5-20 and AX values af-
ter challenge.25
Our patients had stable mild-to-moderate persistent asthma, as
reflected by the mean value of 0.76 for ACQ scores at initial
screening, which is close to the 0.75 cutoff value for well-
controlled disease.19 The normal mean FENO value of 27 ppb at
screening is indicative of the suppressive effects of ICSs at a
mean beclomethasone-equivalent dose of 550 mg/d.26 Despite
this, our patients had impairment of airway function in terms of
FEV1 (80% of predicted value), FEV1/forced vital capacity ratio
(0.72), and R5 (177% of predicted value), along with evidence of
abnormal small-airways function on the basis of their R5-20
(0.18 kPa$L21$s), AX (1.92 kPa$L21), and FEF25-75 (48% of pre-
dicted value) values. It has previously been found that peripheral
airway dysfunction as R5-20 (>0.07 kPa$L21$s) and FEF25-75
(<70% of predicted value) is associated with poorer long-term
asthma control in patients with a preserved FEV1 of greater
than 80% of predicted value.4
We did not initially screen patients for bronchodilator revers-
ibility as an inclusion criterion because this is not something that
is routinely done in our everyday clinical practice. It is conceiv-
able that had we evaluated a group of patients with more severe
disease, more impaired airway function, and greater reversibility,
there might also have been a more pronounced difference in IOS
outcomes. Another possibility to accentuate the signal might be to
compare the formulations after methacholine bronchial challenge
to assess whether the differences in IOS outcomes become more
apparent in the presence of increased airway tone to better reflect
what happens in the setting of an acute episode of bronchocon-
striction in conjunctionwith distal air trapping.6 Another possibil-
ity would be to measure static lung volumes by using
plethysmography (eg, residual volume/total lung capacity) or
perhaps ventilation heterogeneity with nitrogen washout.1
We found that IOS was more sensitive than spirometry to
effects of particle sizewhen comparing formulations after chronic
dosing; indeed, we found no significant differences in FEV1,
FEF25-75, or domiciliary PEF values. The apparent disconnect be-
tween IOS and spirometry outcomes might simply reflect our
IOS-based selection criteria for inclusion as an R5 value of
greater than 150% and an R5-20 value of greater than
0.05 kPa$L 21$s. We have previously shown in terms of either
bronchoconstriction or bronchodilation that the signal/noise ratio
is generally superior for IOS compared with spirometry.20 Our
finding of no significant overall difference (ie, over 60 minutes)
in IOS outcomes after single dosing is in keeping with those of
Houghton et al,27 who also showed no difference in IOS, plethys-
mographic, or spirometry outcomes over 90 minutes of recovery
after methacholine challenge when comparing single doses of
small-particle HFA-formoterol versus coarse-particle formoterol
dry powder, although this was in unselected patients with mild-
to-moderate persistent asthma. Like our single-dose data, they
showed no further decrease in R5 values 15 minutes after single
dosing.We duly acknowledge that using separate ICS and LABA
inhalers is not in keeping with current asthma management
guidelines. The rationale here was to keep the ICS moiety as a
reference while varying the LABA. We elected to use large-
particle ICSs as the reference because it was considered that we
might not see any further improvements in IOS outcomes with
small-particle formoterol in addition to small-particle ICSs. In the
present study one might argue that there was an unopposed effect
of small-particle formoterol in the small airways in conjunction
with large-particle ICSs. This being the case, one might predict a
greater degree of tachyphylaxis of response because of the lack of
ICSs in terms of reversing b2-receptor downregulation in the
distal airways. In fact, we observed a greater IOS response after
chronic dosing with formoterol than salmeterol, suggesting that
this was unlikely to be the case.
In chronic dosing studies comparing small-particle
beclomethasone-formoterol pressurized metered-dose inhaler
versus large-particle fluticasone-salmeterol dry powder inhaler,
there was a significant improvement in methacholine hyper-
responsiveness and a significant reduction in closing volumewith
the former.28,29 However, such studies with combination inhalers
cannot distinguish between the effects of ICS and LABAmoieties
per se.
In summary, the results of the present study have demonstrated
significant differences in IOS outcomes, but not spirometry or
PEF results, after repeated dosing with small-particle formoterol
compared with large-particle salmeterol when given in addition to
ICSs to patients with controlled mild-to-moderate persistent
asthma. We believe this difference in IOS outcomes might be
due in part to improved global deposition of small particles to the
entire lung, including the smaller airways.
Clinical implications: Improved total and peripheral lung depo-
sition with small-particle formoterol than large-particle salme-
terol might translate into better outcomes measured by using
IOS, which are not evident on spirometry.REFERENCES
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TABLE E1. Percentage change from baseline over 60 minutes
after the first dose
Salmeterol
(% change)
Formoterol
(% change) Difference (%)
P
value
FEV1 7.63 8.55 0.92 (24.09 to 5.94) .70
FEF25-75 15.23 31.24 16.01 (22.65 to 34.68) .09
R5 23.51 25.20 1.70 (24.99 to 8.38) .60
R20 9.92 11.99 2.10 (23.12 to 7.26) .41
R5-R20 49.32 50.28 0.97 (212.16 to 14.10) .88
X5 31.51 36.76 5.26 (24.32 to 14.84) .26
RF 27.83 29.08 1.25 (25.77 to 8.27) .71
AX 56.55 60.44 3.89 (27.36 to 15.14) .47
Mean values are shown for each drug, as well as the difference (as 95% CIs).
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